Ladarixin - Dompe Farmaceutici

Drug Profile

Ladarixin - Dompe Farmaceutici

Alternative Names: DF-2156A; DF-2156Y; Meraxin

Latest Information Update: 30 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dompe Farmaceutici
  • Class Small molecules; Sulfonamides
  • Mechanism of Action Interleukin 8A receptor antagonists; Interleukin 8B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 1 diabetes mellitus
  • Discontinued Bullous pemphigoid; Malignant melanoma; Spinal cord injuries

Most Recent Events

  • 30 Jan 2018 Phase-II development for Type-I diabetes mellitus (Newly diagnosed) is ongoing in Italy (PO) (EudraCT2014-003968-20) (NCT02814838)
  • 30 Jan 2018 Phase-II clinical trials in Type-1 diabetes mellitus (Newly diagnosed) in Belgium and Germany (PO) before January 2018 (NCT02814838) (EudraCT2014-003968-20)
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top